Apollo Hospitals Q1FY26 net profit jumps 42% to Rs 433 crore

Apollo Hospitals

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Apollo Hospitals Enterprise Ltd. reported a 42% year-on-year surge in consolidated net profit to ₹433 crore for the quarter ended June 30, 2025, driven by robust performance across its core healthcare services, diagnostics, and digital health businesses.

Revenue rose 15% YoY to ₹5,842 crore, while EBITDA grew 26% to ₹852 crore, reflecting margin expansion and operational efficiencies. The company’s core healthcare services or hospital division contributed ₹2,935 crore in revenue, up 11%, with EBITDA at ₹718 crore. The EBITDA margin stood at 24.5%. Apollo has 8,030 beds across the network (excluding AHLL & managed beds). Overall occupancy was 65%, down from 68% YoY.

Apollo HealthCo, its digital and pharmacy arm, posted a 19% revenue growth to ₹2,472 crore and swung to a ₹57 crore profit from a ₹13 crore loss a year earlier. Apollo Health and Lifestyle Ltd. narrowed its loss to ₹8 crore on a 19% revenue increase.

Chairman Dr. Prathap C Reddy attributed the strong results to Apollo’s integrated care model and strategic investments in digital platforms and infrastructure. “Our three growth engines—Healthcare Services, Retail Health & Diagnostics, and Digital & Pharma Distribution—have all contributed meaningfully,” he said.

Apollo 24/7, the company’s digital health platform, recorded a quarterly GMV of ₹682 crore, up 23% YoY, while the group added 116 new pharmacy stores, taking the total to 6,742.

Looking ahead, Apollo plans to add over 4,300 beds over the next five years with an investment of ₹7,600 crore, including expansions in Bengaluru and Hyderabad. The company also launched Apollo Zen, an AI-powered preventive health program, and OraLife for early oral cancer detection.

The board approved the demerger of its digital health and pharmacy business into Apollo Healthtech Ltd., aimed at unlocking value and enabling focused capital allocation.